--- title: "Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock" type: "News" locale: "en" url: "https://longbridge.com/en/news/286877509.md" description: "Oruka Therapeutics SVP Arjun Agarwal sold 10,290 shares at $59.07 each, totaling $607,830.30, representing a 38.55% decrease in his ownership. Post-sale, he holds 16,406 shares valued at $969,102.42. The transaction was made under a Rule 10b5-1 plan and disclosed to the SEC. The stock is currently trading down 5.8% at $58.34." datetime: "2026-05-19T08:21:28.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286877509.md) - [en](https://longbridge.com/en/news/286877509.md) - [zh-HK](https://longbridge.com/zh-HK/news/286877509.md) --- # Oruka Therapeutics (NASDAQ:ORKA) SVP Sells $607,830.30 in Stock Oruka Therapeutics, Inc. (NASDAQ:ORKA - Get Free Report) SVP Arjun Agarwal sold 10,290 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $59.07, for a total transaction of $607,830.30. Following the completion of the sale, the senior vice president directly owned 16,406 shares of the company's stock, valued at $969,102.42. This trade represents a 38.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Arjun Agarwal also recently made the following trade(s): - On Monday, March 16th, Arjun Agarwal sold 395 shares of Oruka Therapeutics stock. The stock was sold at an average price of $41.30, for a total value of $16,313.50. ## Oruka Therapeutics Trading Down 5.8% Shares of NASDAQ:ORKA opened at $58.34 on Tuesday. Oruka Therapeutics, Inc. has a 1 year low of $9.54 and a 1 year high of $91.00. The business has a fifty day simple moving average of $55.67 and a 200 day simple moving average of $39.63. The firm has a market cap of $3.52 billion, a price-to-earnings ratio of -30.07 and a beta of -0.20. * * * * * * Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.52) by $0.04. On average, sell-side analysts forecast that Oruka Therapeutics, Inc. will post -2.15 EPS for the current year. ## Wall Street Analyst Weigh In Several brokerages recently weighed in on ORKA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Oruka Therapeutics in a research report on Tuesday, April 21st. Barclays raised their target price on Oruka Therapeutics from $78.00 to $160.00 and gave the company an "overweight" rating in a report on Monday, April 27th. UBS Group raised their target price on Oruka Therapeutics from $75.00 to $100.00 and gave the company a "buy" rating in a report on Tuesday, April 28th. BTIG Research restated a "buy" rating and set a $151.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 14th. Finally, Wedbush set a $165.00 target price on Oruka Therapeutics in a report on Monday, April 27th. Ten investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $120.80. **Check Out Our Latest Report on Oruka Therapeutics** ## Hedge Funds Weigh In On Oruka Therapeutics A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Royal Bank of Canada increased its stake in Oruka Therapeutics by 47.2% during the fourth quarter. Royal Bank of Canada now owns 1,139 shares of the company's stock valued at $34,000 after acquiring an additional 365 shares during the period. Kennedy Capital Management LLC increased its stake in Oruka Therapeutics by 0.9% during the fourth quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company's stock valued at $1,476,000 after acquiring an additional 420 shares during the period. AlphaCentric Advisors LLC increased its stake in Oruka Therapeutics by 5.8% during the first quarter. AlphaCentric Advisors LLC now owns 11,506 shares of the company's stock valued at $564,000 after acquiring an additional 626 shares during the period. Russell Investments Group Ltd. increased its stake in Oruka Therapeutics by 35.0% during the fourth quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company's stock valued at $92,000 after acquiring an additional 788 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company's stock valued at $71,000 after buying an additional 904 shares during the period. Institutional investors own 56.44% of the company's stock. ## About Oruka Therapeutics (Get Free Report) Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company's proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.” The company's lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy. ## Read More - Five stocks we like better than Oruka Therapeutics - Why Applied Optoelectronics Stock May Be Near a Turning Point - From High-Yield to High-Growth: 3 Stocks Boosting Dividends - Is Everspin Technologies the Next AI Edge Breakout? - 5 Robotics Stocks to Watch as Physical AI Builds Momentum _This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to \[email protected\]._ Insider Buying or Selling at Oruka Therapeutics? Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Oruka Therapeutics and related companies. From Our Partners SpaceX eyes a 1.75 trillion valuation - here's what to know Elon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a... Brownstone Research Iran's New Leader Just Said Something That Should Terrify Every American Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ... American Alternative $30 stock to buy before Starlink goes public (WATCH NOW!) In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno... Paradigm Press Trump's gold order: the announcement they won't put on the front page On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb... Reagan Gold Group My feud with Zohran Mamdani Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac... Stansberry Research Iran War Shock: What I Was Told In That Private Meeting You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th... Banyan Hill Publishing Why this tiny stock may move before the SpaceX IPO drops The projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio... Behind the Markets SpaceX IPO hides a much bigger story The SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ... Weiss Ratings ### Related Stocks - [ORKA.US](https://longbridge.com/en/quote/ORKA.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [BCS.US](https://longbridge.com/en/quote/BCS.US.md) - [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md) - [UBS.US](https://longbridge.com/en/quote/UBS.US.md) - [RY.US](https://longbridge.com/en/quote/RY.US.md) ## Related News & Research - [Barclays Remains a Buy on Oruka Therapeutics (ORKA)](https://longbridge.com/en/news/286389801.md) - [AbbVie Inc. $ABBV Shares Purchased by RiverFront Investment Group LLC](https://longbridge.com/en/news/286750290.md) - [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md) - [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)